Human Binding Molecules Against CD1a
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current murine antibodies targeting CD1a are limited due to short serum half-life and immune reactions in humans, necessitating the development of human binding molecules for effective diagnosis and treatment of CD1a-associated disorders.
Innovation Solution
Human binding molecules, such as monoclonal antibodies, are identified and developed using phage display technology to specifically target CD1a, offering improved affinity and reduced immune response compared to murine antibodies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If murine antibodies are used to target CD1a, then specific binding to CD1a is achieved, but short serum half-life and immune reactions occur in humans
Solution Approach 1:
The patent applies parameter changes by modifying the antibody's species origin from murine to human. This fundamental parameter change in the antibody's biological origin resolves the contradiction by enabling human antibodies to bind specifically to human CD1a while avoiding immune rejection and achieving appropriate serum half-life characteristics for therapeutic use
2Reliability
If murine antibodies are used to target CD1a, then specific binding to CD1a is achieved, but immune reactions are elicited in humans
Solution Approach 1:
The patent changes the species parameter of the antibody from murine to human, which eliminates the foreign antigenic determinant that triggers HAMA reactions. This parameter change allows the antibody to maintain CD1a binding specificity while being immunologically compatible with human patients
3Object-affected harmful factors
If chimeric or humanized antibodies are used, then immune reaction is reduced, but some murine sequences remain causing unwanted immune response
Solution Approach 1:
The patent extracts and eliminates the remaining murine sequences from chimeric and humanized antibody constructs. By completely removing the foreign murine antigenic determinants while preserving the CD1a-binding variable regions, the invention achieves fully human antibodies that maintain binding specificity without triggering immune responses
Data Source
AI summary
The present invention provides human binding molecules that specifically bind to CD1a, nucleic acid molecules encoding the human binding molecules, compositions comprising the human binding molecules and methods of identifying or producing the human binding molecules. The human binding molecules can be used in the diagnosis, prevention and treatment of neoplastic disorders and diseases.